Molecular Checkpoints of Nucleic Acid Sensing in Tumor Cells: Linking Innate Immune Evasion to Precision Cancer Immunotherapy

Tumor cells possess nucleic-acid sensing systems that detect aberrant DNA and RNA arising from genomic and transcriptomic dysregulation. Cytosolic DNA and RNA sensors, together with endosomal nucleic acid sensors, can induce type I interferons, inflammatory chemokines, antigen presentation programs, and immune cell recruitment. Yet many tumors remain immunologically silent despite harboring potentially immunostimulatory nucleic acids, indicating that malignant cells can restrain these pathways at multiple levels. Nucleic acid clearance, selective RNA editing and remodeling, extracellular second messenger degradation, and epigenetic silencing can suppress these responses. These regulatory layers may favor immune-poor tumor states and limit responsiveness to immune checkpoint blockade. Therapeutic reactivation must be spatially and temporally controlled, because persistent signaling can undergo maladaptive rewiring. We review these molecular brakes, therapeutic strategies to restore innate sensing, and a proposed biomarker framework integrating sensor competence, suppressor activity, and functional immune output. We distinguish the effects arising within tumor cells from those mediated by sensing mechanisms in neighboring host cells and discuss cellular and spatial context, signaling dynamics, and safety. The proposed framework for matching treatments to patients remains investigational and requires prospective clinical validation.